Exelixis, Inc. — Form 10-K Summary
Period note: The request identifies “2012 Q4,” but the supplied filing is Exelixis’s Form 10-K for fiscal 2013, the 52-week year ended December 27, 2013. The filing presents annual results on a calendar-year basis. It also includes unaudited fourth-quarter figures.
Business context and reporting period
Exelixis is a cancer-focused biotechnology company. Its lead drug, COMETRIQ (cabozantinib), was approved in the U.S. for progressive, metastatic medullary thyroid cancer (MTC) in November 2012 and launched in January 2013. The company concentrated proprietary research and commercialization resources on cabozantinib; its other lead asset, cobimetinib, is partnered with Genentech.
Cabozantinib had four ongoing Phase 3 trials beyond MTC: two in castration-resistant prostate cancer (CRPC), one in renal cell cancer (RCC), and one in hepatocellular cancer (HCC). Cobimetinib was in a Phase 3 melanoma trial led by Roche/Genentech. The filing anticipated top-line results from four pivotal trials in 2014.
Financial results and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Total revenue | $31.3 million | $47.5 million |
| Net product revenue | $15.0 million | None reported |
| Research and development | $178.8 million | $128.9 million |
| Selling, general and administrative | $51.0 million | $31.8 million |
| Operating loss | $200.7 million | $122.4 million |
| Net loss | $244.8 million | $147.6 million |
| Operating cash flow | $(198.8) million | $(123.1) million |
| Cash and investments | $415.9 million | $634.0 million |
| Working capital | $178.8 million | $350.8 million |
COMETRIQ’s 2013 gross margin was 93%, based on $15.0 million of net product revenue and $1.1 million of cost of goods sold. Revenue fell 34% year over year as collaboration and license revenue declined; 2012 included a Merck technology-transfer revenue item and a Daiichi Sankyo milestone. Research and development costs rose 39%, mainly from Phase 3 trial activity, while SG&A rose 60%, reflecting commercialization costs and other increases. Interest expense increased to $45.3 million from $27.1 million. The 2011 profit was an unusual exception, driven largely by accelerated collaboration revenue following agreement terminations.
Year-end cash and investments included restricted balances; cash and cash equivalents alone were $104.0 million. Debt had a $347.2 million carrying value at year-end. The company reported $483.6 million of total consolidated indebtedness through maturity. It had a $287.5 million principal amount of 4.25% convertible notes due 2019, $114.0 million principal outstanding under Deerfield notes, and $82.1 million outstanding under its Silicon Valley Bank facility. Management expected available cash, investments, and product revenue to fund operations for at least 12 months after year-end 2013, while warning that future capital needs remained substantial.
Unaudited fourth-quarter figures reported in the filing: revenue $4.3 million, gross profit $4.1 million, operating loss $59.5 million, net loss $70.7 million, and loss per share of $0.38. For the comparable 2012 quarter, revenue was $7.8 million, operating loss $42.0 million, net loss $52.2 million, and loss per share $0.28.
Outlook, commentary, risks, and unusual items
- Management expected 2014 top-line data from COMET-1 and COMET-2 in CRPC and an overall-survival analysis from the MTC EXAM trial. Roche/Genentech expected 2014 top-line results from the cobimetinib melanoma Phase 3 trial. The company said it did not expect significant contingent or milestone payments in 2014.
- COMETRIQ received a positive CHMP opinion in December 2013 for MTC in Europe; European Commission approval was still pending. The drug’s U.S. list price was $10,395 per 28-day supply as of October 2013. The label includes boxed warnings for gastrointestinal perforations and fistulas, and severe hemorrhage.
- Key risks include clinical-trial failure or delay, uncertain market adoption and reimbursement, competition, reliance on third-party manufacturing and distribution, and dependence on collaboration milestones. Revenue was concentrated: Bristol-Myers Squibb represented 52% and Diplomat Specialty Pharmacy 45% of 2013 revenue.
- Financing and covenant risks are material. Silicon Valley Bank required collateral balances tied to outstanding borrowings; a covenant breach could accelerate debt. The company reported $13.5 million of remaining restructuring facility charges, net of sublease income, and expected approximately $0.9 million of additional restructuring charges.
- After year-end, Exelixis raised approximately $75.6 million net by issuing 10.0 million shares in January 2014. A January 2014 Deerfield amendment provided an option to extend $100 million of notes to 2018, subject to higher interest and other terms, and included warrants for 1.0 million shares at $9.70 per share.
- The filing reported no material legal proceedings, no material off-balance-sheet arrangements, and unqualified audit opinions on the financial statements and internal controls.
Investor facts to verify
- Confirm the filing period: this is fiscal 2013, not a 2012 Q4 filing; reconcile the quarter figures to the original filing’s fiscal-quarter presentation.
- Track 2014 pivotal-trial readouts and the MTC survival analysis, including whether endpoints and safety results support regulatory filings.
- Assess the growth and sustainability of COMETRIQ sales, patient access, reimbursement, and commercial costs against the small estimated U.S. MTC market.
- Review unrestricted versus restricted liquidity, cash burn, SVB collateral requirements, and repayment or extension terms for Deerfield and convertible debt.
- Monitor revenue concentration and whether collaboration milestones, royalties, or partnered programs generate cash; the stated approximately $2.4 billion of potential contingent payments was non-risk-adjusted and dependent on partner achievements.